Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Myriad Genetics, |
RCV003449989 | SCV004187037 | pathogenic | Lynch syndrome 1 | 2023-07-27 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |
Department of Pathology and Laboratory Medicine, |
RCV001354085 | SCV001548613 | pathogenic | Endometrial carcinoma | no assertion criteria provided | clinical testing | The MSH2 p.Ala154GlnfsX20 variant was not identified in the literature nor was it identified in the following databases: dbSNP, ClinVar, UMD-LSDB, the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.459del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 154 and leads to a premature stop codon 20 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. | |
Department of Pathology and Laboratory Medicine, |
RCV001357715 | SCV001553266 | pathogenic | Carcinoma of colon | no assertion criteria provided | clinical testing | The MSH2 p.Ala154GlnfsX20 variant was not identified in the literature nor was it identified in the following databases: dbSNP, ClinVar, UMD-LSDB, the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.459del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 154 and leads to a premature stop codon 20 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. | |
Department of Pathology and Laboratory Medicine, |
RCV001358629 | SCV001554420 | pathogenic | Lynch syndrome | no assertion criteria provided | clinical testing | The MSH2 p.Ala154GlnfsX20 variant was not identified in the literature nor was it identified in the following databases: dbSNP, ClinVar, UMD-LSDB, the Exome Aggregation Consortium (August 8th 2016) or the Genome Aggregation Database (Feb 27, 2017). The c.459del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 154 and leads to a premature stop codon 20 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the MSH2 gene are an established mechanism of disease in Lynch Syndrome and is the type of variant expected to cause the disorder. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic. |